We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Beactica Initiates Drug Discovery Collaboration with Medivir
News

Beactica Initiates Drug Discovery Collaboration with Medivir

Beactica Initiates Drug Discovery Collaboration with Medivir
News

Beactica Initiates Drug Discovery Collaboration with Medivir

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Beactica Initiates Drug Discovery Collaboration with Medivir"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Beactica has announced that it has entered into an agreement with Medivir AB. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial terms of the agreement were not disclosed.

“We are pleased that Medivir has selected Beactica to advance one of their prioritized discovery programmes”, said Beactica CEO, Dr Per Källblad. “Medivir is at a very exciting point in their development and we are looking forward to tackle this challenging project together with their team of innovative scientists”.

Dr Richard Bethell, Executive Vice President Discovery Research, Medivir commented: “We at Medivir are very much looking forward to collaborating with our partners at Beactica, and applying their fragment-based lead discovery technology, in our search for hits active against one of our early discovery targets".

Advertisement